Involvement of microsomal triglyceride transfer protein in nonalcoholic steatohepatitis in novel spontaneous mouse model
- PMID: 20392512
- DOI: 10.1016/j.jhep.2009.12.033
Involvement of microsomal triglyceride transfer protein in nonalcoholic steatohepatitis in novel spontaneous mouse model
Abstract
Background & aims: Nonalcoholic fatty liver disease (NAFLD) is currently recognized as a global health issue and encompasses a wide spectrum of entities, ranging from simple hepatic steatosis to nonalcoholic steatohepatitis (NASH). The lack of a spontaneous animal model of NASH, however, has hampered basic research in this field.
Methods: We examined the hepatic lesions in the inbred Fatty Liver Shionogi (FLS) mouse, which exhibits type 2 diabetes, and investigated the molecular mechanism leading to NAFLD/NASH. Using vector-mediated hepatic expression of microsomal triglyceride transfer protein (MTP), a key molecule for very low density lipoprotein (VLDL) assembly and export, its contribution to the hepatic lesions as well as to glucose intolerance was examined.
Results: The FLS mouse, maintained on normal chow, exhibited excessive hepatic triglyceride (TG) accumulation due to impaired VLDL secretion, and subsequently hepatic lesions comparable to NASH, with increased expression of inflammatory molecules as well as insulin resistance. Gene expression and Western blot analyses demonstrated reduced hepatic expression of MTP in the FLS mouse. Hepatic induction of MTP resulted in a reduction in hepatic TG accumulation, improvement of VLDL export, and amelioration of NASH-like lesions, as well as glucose intolerance.
Conclusions: These data suggest that the FLS mouse could serve as a spontaneous model of NASH with insulin resistance, and that reduced MTP is involved in the development of NASH, pointing towards MTP as a critical target for the prevention and treatment of NASH.
Copyright 2010 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Similar articles
-
Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis.Hepatology. 2007 Jun;45(6):1366-74. doi: 10.1002/hep.21655. Hepatology. 2007. PMID: 17476695
-
Lipoprotein metabolism mediates the association of MTP polymorphism with beta-cell dysfunction in healthy subjects and in nondiabetic normolipidemic patients with nonalcoholic steatohepatitis.J Nutr Biochem. 2010 Sep;21(9):834-40. doi: 10.1016/j.jnutbio.2009.06.007. Epub 2009 Sep 4. J Nutr Biochem. 2010. PMID: 19733470
-
Hepatic insulin resistance is associated with increased apoptosis and fibrogenesis in nonalcoholic steatohepatitis and chronic hepatitis C.J Hepatol. 2011 Jan;54(1):142-52. doi: 10.1016/j.jhep.2010.06.021. Epub 2010 Aug 27. J Hepatol. 2011. PMID: 20888662
-
Microsomal triglyceride transfer protein and nonalcoholic fatty liver disease.Expert Rev Gastroenterol Hepatol. 2011 Apr;5(2):245-51. doi: 10.1586/egh.11.22. Expert Rev Gastroenterol Hepatol. 2011. PMID: 21476919 Review.
-
Hepatic triglyceride synthesis and nonalcoholic fatty liver disease.Curr Opin Lipidol. 2008 Jun;19(3):295-300. doi: 10.1097/MOL.0b013e3282ff5e55. Curr Opin Lipidol. 2008. PMID: 18460922 Review.
Cited by
-
Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis.Sci Rep. 2017 Feb 14;7:42477. doi: 10.1038/srep42477. Sci Rep. 2017. PMID: 28195199 Free PMC article.
-
How Useful Are Monogenic Rodent Models for the Study of Human Non-Alcoholic Fatty Liver Disease?Front Endocrinol (Lausanne). 2016 Nov 16;7:145. doi: 10.3389/fendo.2016.00145. eCollection 2016. Front Endocrinol (Lausanne). 2016. PMID: 27899914 Free PMC article. Review.
-
Ezetimibe prevents the development of non‑alcoholic fatty liver disease induced by high‑fat diet in C57BL/6J mice.Mol Med Rep. 2014 Dec;10(6):2917-23. doi: 10.3892/mmr.2014.2623. Epub 2014 Oct 10. Mol Med Rep. 2014. PMID: 25310357 Free PMC article.
-
Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics.Lipids Health Dis. 2024 Apr 2;23(1):95. doi: 10.1186/s12944-024-02092-2. Lipids Health Dis. 2024. PMID: 38566209 Free PMC article. Review.
-
The effect of the severity of liver cirrhosis on the level of lipids and lipoproteins.Clin Exp Med. 2014 Nov;14(4):417-21. doi: 10.1007/s10238-013-0262-5. Clin Exp Med. 2014. PMID: 24122348 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous